Elisa Arribas Rodríguez

Elisa Arribas Rodríguez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Albert MoralesAlbert Morales
Albert Morales
SRSilvia Rojo Rello
Silvia Rojo Rello
HCHelena Cristóbal
Helena Cristóbal
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
Pablo García de FrutosPablo García de Frutos
Pablo García de Frutos
Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.

Verified
Journal Article
Open access
PDF file
AVAlvaro Tamayo Velasco
Alvaro Tamayo Velasco
MPMaría Jesús Peñarrubia-Ponce
María Jesús Peñarrubia-Ponce
F. JAVIER ALVAREZF. JAVIER ALVAREZ
F. JAVIER ALVAREZ
HGHugo Gonzalo
Hugo Gonzalo
IGIGNACIO DE LA FUENTE GRACIANI
IGNACIO DE LA FUENTE GRACIANI
EGEsther Gómez-Sánchez
Esther Gómez-Sánchez
Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments.

1 January 2021
Verified
Book Chapter
Closed access
EAEduardo Arranz
Eduardo Arranz
ÁPÁngel De Prado
Ángel De Prado
AFAida Fiz-López
Aida Fiz-López
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
JGJosé A Garrote
José A Garrote
DBDavid Bernardo
David Bernardo

22 January 2025 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
ÁPÁngel De Prado
Ángel De Prado
BABEATRIZ DE ANDRÉS-ASENJO
BEATRIZ DE ANDRÉS-ASENJO
BVBenito Velayos
Benito Velayos
JBJESÚS BARRIO
JESÚS BARRIO
DBDavid Bernardo
David Bernardo
Ulcerative colitis (UC) is an inflammatory disorder of the gastrointestinal tract. Although Tofacitinib, which inhibits the JAK1 and JAK3 signalling pathway, is approved to treat patients with UC, its specific mechanism of action remain elusive. Given the central role that conventional dendritic cells (cDC) elicit in gut homeostasis, we hypothesised that Tofacitinib acts modulating cDC function in UC. Human biopsies were obtained from colon of controls, and patients with UC (active and quiescent). Lamina propria mononuclear cells (LPMC) were ex-vivo cultured in the presence/absence of Tofacitinib. The specific effect elicited over human intestinal cDC, monocytes and macrophages was assessed by flow cytometry. cDC were also enriched following Tofacitinib conditioning in order to assess its effect over naïve T-cells. Several human intestinal cDC, monocyte and macrophage subsets can be found in the human colon, with these cells being more similar between controls and patients with qUC referred to patients with aUC. Following ex-vivo culture, Tofacitinib downregulated JAK1 expression on intestinal monocytes from patients with both active and quiescent UC. As for macrophages, JAK1 was decreased on patients with active UC while JAK was downregulated on macrophages from patients with quiescent disease. Tofacitinib did not modulate the phenotype or function of human intestinal cDC. Tofacitinib does not modulate the phenotype and function of human intestinal cDC in UC. On the contrary, it displays a differential capacity to modulate intestinal monocyte and macrophage phenotype. Future studies should address whether it also translates into a differential function of these cells.

4 November 2025 in Microbiologyopen
Verified
Journal Article
Open access
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
MGMaría García‐Pizarro
María García‐Pizarro
ÁPÁngel De Prado
Ángel De Prado
MSMaría Santiago‐Carretero
María Santiago‐Carretero
Marta HernandezMarta Hernandez
Marta Hernandez
SCSara Cuesta-Sancho
Sara Cuesta-Sancho
Inflammatory bowel disease is associated with complex changes in the intestinal microbiota. While bacterial dysbiosis has been widely studied, the role of fungal communities and their interaction with bacteria remains less explored. This study aims to characterize both bacterial and fungal populations in patients with Crohn's disease and ulcerative colitis, identifying potential microbial biomarkers and inter‐kingdom interactions related to disease activity. We analysed paired intestinal tissue and faecal samples from patients with inflammatory bowel disease. Bacterial, fungal and viral composition were assessed by 16S, ITS DNA and shotgun sequencing, respectively. Bioinformatics analyses were done using Qiime2 and R studio platforms. PERMANOVA and ANOSIM analyses revealed significant compositional differences between faecal and mucosal samples in most groups. Several genera were consistently shared across tissues, while others showed tissue‐ or disease‐specific distributions. Exploratory correlations between bacteria and fungi revealed that Wallemia could play a role in balancing the presence of potentially beneficial and pathogenic bacteria. Importantly, Prevotella was associated with active disease, Fusobacterium with active Crohn's disease, and Roseburia with remission in ulcerative colitis, supporting their potential as biomarkers. All these hypotheses should be further tested in future studies. Our findings reveal distinct microbial signatures in inflammatory bowel disease that could promote the intestinal dysbiosis hypotheses perpetuate chronic intestinal inflammation. The identification of faecal biomarkers may complement approaches for noninvasive monitoring of disease activity. These results underscore the need for further research into bacteria‐fungi interactions and their role in gut inflammation.

Verified
Journal Article
Open access
PDF file
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
JCJavier Casas
Javier Casas
SGSara Gutiérrez González
Sara Gutiérrez González
German PerdomoGerman Perdomo
German Perdomo
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4+ and CD4−), and, to a lower extent, in B-cells from healthy controls. Notably, IDE’s surface expression was upregulated on monocytes from COVID-19 patients at diagnosis, and it was increased in more severe patients. However, IDE’s surface expression was downregulated (relative to healthy controls) 3 months after hospital discharge in all the studied immune subsets, with this effect being more pronounced in males than in females, and thus it was sex-dependent. Additionally, IDE levels in monocytes, CD4+ T-cells, and CD4− T-cells were inversely correlated with circulating insulin levels in COVID-19 patients (both at diagnosis and after hospital discharge). Of note, high glucose and insulin levels downregulated IDE surface expression by ~30% in the monocytes isolated from healthy donors, without affecting its expression in CD4+ T-cells and CD4− T-cells. In conclusion, our studies reveal the sex- and metabolism-dependent regulation of IDE in monocytes, suggesting that its regulation might be important for the recruitment of immune cells to the site of infection, as well as for glucometabolic control, in COVID-19 patients.